August 21, 2024, Covington Alert

On August 15, 2024, the Food and Drug Administration’s (FDA’s) Center for Food Safety and Nutrition (CFSAN) took another important step in its sodium reduction efforts by issuing a Draft Guidance that contains new voluntary targets for sodium reduction in foods. The Draft Guidance builds on FDA’s October 2021 Final Guidance on Voluntary Sodium Reduction Goals, which established short-term voluntary targets for reducing sodium in commercially processed, packaged and prepared food. The Draft Guidance proposes new three-year sodium reduction targets for 16 overarching food categories and 163 subcategories that are commercially processed and packaged, or prepared in food service establishments such as restaurants. 

Background

Average sodium intake in the United States is currently almost 50% more than the recommended limit.[1]  To help reduce sodium across the food supply, FDA has taken an iterative, step-wise approach that includes establishing voluntary sodium targets for industry, monitoring and evaluating progress, and engaging with stakeholders.

FDA’s sodium reduction efforts began in 2016, when it released draft guidance on the agency’s short-term and long-term goals for sodium reduction in a variety of commercially processed, packaged, or prepared foods. FDA issued final guidance on this topic in October 2021 (Final Guidance), in which it set a goal of reducing average sodium intake from over 3,400 mg/day to 3,000 mg/day. As of 2022, about 40% of the targets set for foods in the Final Guidance had been reached.[2]  FDA has deemed the Final Guidance “Phase I” of its sodium reduction efforts.

The Draft Guidance marks the beginning of “Phase II” of FDA’s sodium reduction efforts. The Draft Guidance proposes to reduce average sodium intake from 3,000 mg/day to 2,750 mg/day. This target aligns with the Healthy People 2030 goal of reducing average sodium intake to approximately 2,750 mg/day in the United States by 2030,[3] although it remains above the 2,300 mg/day sodium limit scientific consensus groups and the Dietary Guidelines for Americans recommend to reduce the risk of hypertension and cardiovascular disease.[4] FDA believes that its Phase II targets will “balance the need for broad and gradual reductions in sodium with what is publicly known about technical and market constraints on sodium reduction and reformulation.”[5] Overall, the Phase I and Phase II targets would support reducing average sodium intake in the United States by about 20% from pre-2021 levels. 

Key Elements of Draft Guidance

The Draft Guidance establishes revised, quantitative target concentrations and upper bound concentrations for sodium levels in various identified food categories. The proposed sodium targets apply to 16 overarching food categories and 163 subcategories—including packaged food, processed food, and food served at restaurants. FDA intends for the revised quantitative target concentrations and upper bound concentrations for sodium levels to accomplish five goals:

  • Support increased food choice for consumers by encouraging food reformulation and new product development; 
  • Support the Dietary Guidelines recommendation of limiting sodium intake to 2,300 mg/day by encouraging sodium reduction over the medium term to achieve an average intake of 2,750 mg/day;
  • Provide uniform metrics for voluntary sodium reduction for industry stakeholders;
  • Focus on the total amount of sodium in a given food as opposed to individual sodium-containing ingredients; and
  • Support and extend industry’s voluntary efforts to reduce sodium across the range of commercially processed, packaged, and prepared foods.[6]

Appendix Table 1 of the Draft Guidance summarizes the results of FDA’s analysis of the sodium content of the food supply as of 2022. It also identifies the entire list of food categories and voluntary targets comprising Phase II of FDA’s sodium reduction efforts. This table includes four key elements: food categories, 2022 baseline sodium concentrations, Phase II (3-year) target mean sodium concentrations, and Phase II (3-year) upper bound sodium concentrations. 

  • Food Categories: Phase II contains the same overarching food categories as Phase I. These categories, which are compatible with existing industry and regulatory categories, include “dairy;” “fats, oils, and dressings;” “fruits, vegetables, and legumes;” “cereals;” “bakery products;” and “snacks,” among others. FDA organized these food categories on the basis of contribution to sodium intake, the amount of sodium added to the food, similar functional roles for sodium-containing ingredients, similar technical potential for reduction in sodium content, and compatibility with existing industry and regulatory categories.
  • Baseline Sodium Concentrations: FDA developed its baseline sodium concentrations using (1) label data for packaged foods sold directly to the consumer and menu nutrition data for foods sold in large restaurant chains, and (2) sales volume data for such foods and the total sales of each chain for restaurant food, to ensure that products consumers purchase more frequently count for more in the final average. Each baseline represents FDA’s assessment of the approximate state-of-the-market regarding sodium concentrations in each food category in 2022.
  • Target Mean Sodium Concentrations: FDA has proposed target mean sodium concentrations, in milligrams per 100 grams of food, per food category. In setting these target concentrations, FDA has taken into account concentrations necessary to achieve important food safety functions and functionality roles.
  • Upper Bound Sodium Concentrations: The upper bound sodium concentrations, in milligrams per 100 grams of food, are goals for the highest level of sodium for products in each food category. The upper bound for each food category is influenced by the corresponding target mean concentration and the current distribution of sodium concentrations for products in that food category. The Draft Guidance notes that, when establishing these concentrations, FDA placed an emphasis on maintaining concentrations needed for food safety (e.g., concentrations necessary to allow for the continued use of salt as a food preservative).

The Draft Guidance does not provide in depth recommendations on the technical details of reducing sodium, indicating that the agency will instead continue to rely on industry experts to reformulate products. FDA notes, however, that product reformulations should not negatively affect the nutritional quality of the foods by modifying other nutrient levels, and that reformulations should take into account all Dietary Guidelines recommendations and FDA policies.[7]

Looking Ahead

FDA, in cooperation with other agencies, intends to continue monitoring population sodium intake, as well as the content of sodium in the food supply, and plans to assess progress towards its sodium reduction goals about every three years. The agency will also monitor the levels of other nutrients (e.g., added sugars and saturated fats) to ensure that no broad trends emerge that negatively affect the nutritional quality of foods[8] and will continue discussing with industry the appropriate use of ingredients added to food as part of sodium reduction efforts during product development or reformulation.[9]

Interested parties should submit comments on the Draft Guidance by November 14, 2024.

Covington will closely monitor developments on this issue, particularly any final guidance on long-term sodium targets. If you have any questions concerning the material discussed in this client alert, please contact members of our Food, Beverage, and Dietary Supplements practice.


[1] FDA, Sodium Reduction in the Food Supply: the Public Health Need (Aug. 15, 2024)

[2] Id. See also FDA, Sodium Reduction in the U.S. Food Supply 2010 – 2022: A Preliminary Assessment of Progress (Aug. 15, 2024).

[3] See U.S. Dept. of Health & Hum. Serv., Healthy People 2030 Objective: Reduce consumption of sodium by people aged 2 years and over — NWS‑12.

[4] See U.S. Dept. of Health & Hum. Serv. and U.S. Dept. of Agric., 2020 – 2025 Dietary Guidelines for Americans (9th ed. Dec. 2020).

[5] Draft Guidance at 4.

[6] Id. at 4 – 5. 

[7] Id. at 5. 

[8] Id. at 7. 

[9] Id.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Miriam Guggenheim Miriam Guggenheim

Miriam Guggenheim, co-chair of Covington’s Food, Drug and Device Practice Group, assists a broad range of major food and dietary supplement companies in achieving their marketing goals while minimizing regulatory and litigation risks. She also helps clients successfully navigate crises such as recalls and…

Miriam Guggenheim, co-chair of Covington’s Food, Drug and Device Practice Group, assists a broad range of major food and dietary supplement companies in achieving their marketing goals while minimizing regulatory and litigation risks. She also helps clients successfully navigate crises such as recalls and unwanted Congressional or regulatory attention. In addition to her work for individual clients, Miriam serves as outside counsel to a number of key trade associations, helping them accomplish broad industry objectives by engaging with the FDA, FTC, and Congress. Chambers USA notes, Miriam is “incredibly sharp and very responsive” and a client reports, “I rely on Miriam tremendously to help me find ways forward in difficult and novel situations, and she never fails to deliver.”

As the food industry faces new challenges – including scrutiny of ingredients and food packaging materials, concerns about heavy metals and other contaminants, attention to “ultra-processed food,” and increasing consumer fraud litigation and Prop 65 demand letters – Miriam remains at the forefront of legislative and regulatory changes and food policy and litigation trends. She draws on this deep knowledge and insight to advise clients on all aspects of food development and marketing, from product ingredient sourcing and manufacturing considerations to food labeling and marketing. Partnering with Covington colleagues in international offices, Miriam helps clients solve regulatory problems across the globe.

Photo of Deepti Kulkarni Deepti Kulkarni

Drawing from over a decade of experience working in both FDA’s Office of Chief Counsel and private practice, Deepti Kulkarni provides strategic advice to clients on a wide range of complex matters involving FDA and USDA regulatory oversight. She has played a key…

Drawing from over a decade of experience working in both FDA’s Office of Chief Counsel and private practice, Deepti Kulkarni provides strategic advice to clients on a wide range of complex matters involving FDA and USDA regulatory oversight. She has played a key role in the development and implementation of the regulatory frameworks for alternative proteins as well as bioengineered food and agriculture products.

Deepti advises companies developing and marketing animal products, foods, dietary supplements, and cosmetics at nearly every step of the product lifecycle. She also counsels clients on potential crises, such as product recalls, import refusals, and other regulatory actions.

Deepti previously served as an Associate Chief Counsel in the FDA’s Office of Chief Counsel. While at FDA, she counseled various components of FDA and HHS on a broad scope of issues related to animal products, foods, dietary supplements, and cosmetics, as well as cross-product matters involving imports and exports, advisory committees, and constitutional issues. Deepti received several awards during her time at the FDA, including the FDA Award of Merit (FDA’s highest award), Commissioner’s Special Recognition Award, and the CFSAN Director’s Special Citation Award.

Photo of Jessica O'Connell Jessica O'Connell

Drawing from nearly twenty years of experience working at FDA and in private practice, Jessica O’Connell provides strategic advice to a broad range of companies and trade associations in navigating regulatory frameworks and engaging with food and drug regulatory bodies and Congress. She…

Drawing from nearly twenty years of experience working at FDA and in private practice, Jessica O’Connell provides strategic advice to a broad range of companies and trade associations in navigating regulatory frameworks and engaging with food and drug regulatory bodies and Congress. She works closely with clients to develop product strategies that are low-risk from both a regulatory and litigation perspective while also meeting marketing goals and objectives.

Jessica is based in our Washington, DC office and is vice chair of the Food, Drug, and Device practice group. Chambers USA reports that she “is enthusiastic, exceptionally smart and a talented lawyer who brings tremendous insight from being a regulator” and that she “knows how best to interact with the FDA in a productive and efficient way.”

She assists clients in complying with U.S. regulatory requirements for food, dietary supplements, cosmetics, and OTC drugs, and has specific expertise advising on FDA’s import and export requirements across all product categories. She also regularly counsels clients regarding potential crises, such as recalls, regulator investigations, and other unanticipated regulatory attention.

Jessica has engaged with Congress on cosmetic and drug legislative efforts and alternative protein and other food labeling requirements. She has represented clients in both FDA and FTC investigations, including negotiating consent decrees and responding to civil investigative demands, and in matters before the NAD. Jessica has specific expertise regarding the regulatory framework for new and emerging food technologies, including alternative protein ingredients and products and specialized nutrition products such as infant formula and medical foods, the marketing of cosmetics and OTC drugs, including sunscreens, Proposition 65, organic labeling, the federal and state legal landscapes surrounding the development and marketing of products containing CBD, and claim substantiation requirements, as well as manufacturing and supply chain requirements under FSMA and FDA’s implementation of MoCRA.

Jessica also has an active pro bono practice, with a particular focus on issues relating to reproductive rights and health care access.

Before joining Covington, Jessica served as Associate Chief Counsel in FDA’s Office of Chief Counsel. While at FDA, Jessica counseled various components of FDA and HHS on a broad range of food, cosmetic, and drug legal issues, including FDA’s implementation of FSMA and FDA’s work investigating foodborne illness outbreaks and related actions, including recalls and other enforcement activities. In addition, Jessica provided legal counsel to the agency and Department regarding FDA’s import and export activities for all FDA-regulated products.

Photo of Jeannie Perron Jeannie Perron

Jeannie Perron is a member of the firm’s Food and Drug Practice Group, resident in the Washington, DC Office.

In addition to being an attorney, Jeannie also holds a degree in veterinary medicine and has practiced as a veterinarian.  She specializes in food and

Jeannie Perron is a member of the firm’s Food and Drug Practice Group, resident in the Washington, DC Office.

In addition to being an attorney, Jeannie also holds a degree in veterinary medicine and has practiced as a veterinarian.  She specializes in food and drug law, with a sub-specialty in animal food and drug law.  In this capacity, she represents companies that manufacture feed, feed ingredients, drugs, biologics and medical devices for animals, as well as clients in related industries.

Her specialties also include advising clients and providing representation on matters before the United States Department of Agriculture arising under the Animal Welfare Act.  Her clients are animal research companies, pharmaceutical companies, and animal dealers and exhibitors.

Another specialized area of practice relates to the importation of animal-derived ingredients and products.  Jeannie advises clients on USDA regulations and procedures in this area and assists clients in securing the required permits and certifications.

In addition to these other practice areas, Jeannie also advises clients in the regulation of dietary supplements, over-the-counter drugs, cosmetics for humans, and import and export of products regulated by the United States Food and Drug Administration as well as those having animal or microbially-derived ingredients regulated by USDA. 

Photo of Emily Statham Emily Statham

Emily Statham is an associate in the firm’s Washington, DC office where she is a member of the Food, Drug, and Device Practice Group. She advises pharmaceutical, biotechnology, medical device, food, and animal health companies on a variety of regulatory and compliance issues.…

Emily Statham is an associate in the firm’s Washington, DC office where she is a member of the Food, Drug, and Device Practice Group. She advises pharmaceutical, biotechnology, medical device, food, and animal health companies on a variety of regulatory and compliance issues.

Photo of Krista Hekking Krista Hekking

Krista Hekking is an associate in the firm’s Los Angeles office where she is a member of the Food, Drug, and Device Practice Group. She provides strategic advice to food and dietary supplement manufacturers on a range of product development issues to minimize…

Krista Hekking is an associate in the firm’s Los Angeles office where she is a member of the Food, Drug, and Device Practice Group. She provides strategic advice to food and dietary supplement manufacturers on a range of product development issues to minimize risk of regulatory enforcement and class action litigation. Krista stays abreast of litigation trends and food regulatory developments to provide guidance on food labeling and marketing. She counsels clients regarding favorable regulatory categories for food marketing, whether as conventional foods, dietary supplements, or medical foods, and provides guidance on regulatory requirements for each, including those related to product claims and safety substantiation.

Krista works closely with her transactional colleagues to assist food manufacturers in drafting and negotiating co-manufacturing, supply, and similar agreements. She also assists clients in navigating and successfully resolving food recalls, regulatory enforcement, and inspections. Krista works with local counsel across the globe to help clients meet regulatory requirements, respond to legislative and regulatory proposals, and resolve issues related to enforcement.

Photo of Cory Trio Cory Trio

Cory Trio is an associate in the firm’s Washington, DC office where he is a member of the Food, Drug, and Device Practice Group. Cory helps food, dietary supplement, OTC drug, and consumer product clients navigate a broad range of U.S. regulatory requirements. …

Cory Trio is an associate in the firm’s Washington, DC office where he is a member of the Food, Drug, and Device Practice Group. Cory helps food, dietary supplement, OTC drug, and consumer product clients navigate a broad range of U.S. regulatory requirements. He has wide-ranging expertise on FDA and USDA food safety and manufacturing requirements, including FDA’s Food Safety Modernization Act (FSMA) regulations. He regularly advises clients on the development and implementation of food safety and quality programs and in responding to regulatory inspections, product recalls, and quality events. Cory also counsels clients on product labeling and claim substantiation issues, helping clients advance their marketing goals while mitigating regulatory and litigation risks.

Cory counsels OTC drug manufacturers on product development, labeling, and manufacturing issues, with a particular focus on helping clients navigate the CARES Act OTC monograph reforms. He also advises clients across product categories on FDA’s import and export requirements.